International Journal of Research Publication and Reviews, Vol 5, Issue 10, pp 5148-5161 October 2024

WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Evaluating the Economic and Clinical Impacts of Pharmaceutical Supply Chain Centralization through AI-Driven Predictive Analytics: Comparative Lessons from Large-Scale Centralized Procurement Systems and Implications for Drug Pricing, Availability, and Cardiovascular Health Outcomes in the U.S.

Okolue Chukwudi Anthony[1*], Emmanuel Oluwagbade[1], Adeola Bakare[2] and Blessing Animasahun[3]

[1]Vanderbilt University, Owen Graduate School of Management, USA
[2]Pharmaceutical Economics and Policy, Chapman University, USA
[3]Harbert College of Business, Auburn University, USA
DOI : https://doi.org/10.55248/gengpi.6.0425.14152

ABSTRACT

The rising cost of pharmaceuticals, uneven drug availability, and fragmented procurement mechanisms have created mounting challenges for health systems seeking both economic efficiency and improved patient outcomes. This article critically evaluates the economic and clinical impacts of pharmaceutical supply chain centralization, with a focus on AI-driven predictive analytics as an enabler of more efficient procurement, pricing stabilization, and improved public health—particularly in relation to cardiovascular care. Drawing lessons from large-scale centralized pharmaceutical procurement models implemented in public and private sector health systems, this study examines how AI technologies have supported demand forecasting, supplier negotiation, inventory optimization, and shortage mitigation. Using comparative analysis, the article explores the performance of centralized procurement initiatives—ranging from national formulary consolidation strategies to group purchasing organizations (GPOs)—and assesses their influence on drug availability, price transparency, and clinical adherence. Particular attention is given to cardiovascular medication classes such as antihypertensives, statins, and antiplatelets, where consistent access is critical to achieving population-level health improvements. The discussion further explores how predictive modeling has facilitated the anticipation of demand surges, reduction in stockouts, and prioritization of high-risk patient groups. Evidence suggests that when AI-enabled systems are combined with centralized purchasing, both cost savings and improved medication adherence are achievable at scale. However, concerns regarding data sharing, supplier monopolization, and integration with electronic prescribing systems are noted. The article concludes with actionable insights for health policymakers, procurement consortia, and clinical stakeholders seeking to balance economic control with equitable pharmaceutical access—advancing a framework that links procurement modernization with tangible gains in cardiovascular health outcomes.

Keywords: Centralized Procurement, Predictive Analytics, Drug Availability, Pharmaceutical Supply Chain, Cardiovascular Health, AI in Healthcare

1. INTRODUCTION

1.1 Overview of Pharmaceutical Supply Chain Complexity in the U.S.

The pharmaceutical supply chain in the United States is one of the most expansive and intricately layered healthcare ecosystems in the world. It comprises multiple stakeholders—including manufacturers, distributors, pharmacy benefit managers (PBMs), hospitals, retail pharmacies, and government entities—each with distinct operational and financial incentives [1]. This complex interdependence introduces vulnerabilities related to coordination, inventory visibility, pricing transparency, and demand forecasting.

Drug products may traverse numerous intermediaries before reaching patients, often undergoing repackaging, warehousing, and transportation through third-party logistics providers. These transitions not only increase costs but also obscure accountability and reduce responsiveness during demand surges or supply disruptions [2]. Unlike other industries that benefit from vertically integrated or digitally synchronized supply chains, the U.S. pharmaceutical sector remains heavily fragmented, particularly for generic drugs and sterile injectables.

Moreover, the market is affected by a small number of critical suppliers for many essential medicines, including oncology agents and antibiotics. This supplier concentration—combined with globalized manufacturing—amplifies the risk of single-point failures. Manufacturing issues, regulatory sanctions, or geopolitical tensions in active pharmaceutical ingredient (API) source countries can rapidly destabilize domestic inventories [3].

While some health systems have adopted enterprise resource planning (ERP) tools or group purchasing organizations (GPOs) to streamline sourcing, these measures have only partially mitigated systemic inefficiencies. The lack of centralized oversight, coupled with pricing opacity and inconsistent forecasting tools, continues to challenge supply chain performance [4].

Understanding and redesigning procurement frameworks is increasingly recognized as a critical strategy for achieving supply chain resilience, cost containment, and equitable drug availability.

1.2 Problem Statement: Drug Shortages, Cost Variability, and Inefficiencies

Despite the sophistication of the U.S. pharmaceutical market, drug shortages persist across therapeutic areas, especially for sterile injectables, pediatric medications, and essential generics. Shortages not only disrupt patient care but also lead to treatment delays, substitution errors, and adverse outcomes [5]. Hospitals are often forced to resort to manual allocation or grey-market purchases, exacerbating safety risks and operational costs.

Cost variability is another pervasive issue. Prices for identical medications may differ significantly across regions and institutions due to inconsistent contracting practices, volume guarantees, and PBM rebate structures. This variation undermines formulary standardization and inflates administrative overhead [6].

Procurement inefficiencies are further compounded by the absence of real-time data sharing, predictive analytics, and centralized negotiation. Most institutions operate independently when sourcing pharmaceuticals, limiting economies of scale and reducing collective bargaining power.

These systemic issues demand a coordinated response. Fragmentation in procurement contributes to supply volatility, weakens price leverage, and impairs continuity of care. A centralized procurement approach offers a promising pathway to address these challenges by enhancing transparency, ensuring quality assurance, and promoting equitable distribution across the healthcare network [7].

1.3 Purpose and Scope of the Article

This article examines the role of centralized procurement models in improving the resilience, equity, and efficiency of the U.S. pharmaceutical supply chain. Drawing from public-private partnerships, government initiatives, and multi-institutional consortia, it explores how centralized strategies can counteract drug shortages, reduce price volatility, and improve supply visibility.

Key areas of analysis include:

- Economic rationale and cost containment potential;
- Infrastructure and digital enablers;
- Governance, contracting models, and regulatory frameworks;
- Case studies of successful centralized approaches, such as Civica Rx and the U.S. Strategic Active Pharmaceutical Ingredient Reserve (SAPIR).

The article is intended for policymakers, health system executives, supply chain managers, and procurement officers seeking to realign pharmaceutical sourcing with public health objectives, fiscal sustainability, and patient access imperatives [8].

2. CENTRALIZATION IN PHARMACEUTICAL PROCUREMENT: MODELS AND ECONOMIC THEORY

2.1 Definitions and Types of Centralized Procurement

Centralized procurement refers to the aggregation of purchasing responsibilities under a unified organizational or governmental entity to improve price negotiation, reduce administrative redundancy, and standardize quality assurance. It contrasts with decentralized models, where individual hospitals or clinics independently negotiate with suppliers. Centralized procurement can be implemented at various levels—national, regional, or institutional—depending on governance structure, market size, and regulatory autonomy [6].

National-level centralized procurement is coordinated by a federal government or public health authority and typically targets essential medicines or vaccines. It involves a single-payer system or centralized purchasing agency negotiating directly with manufacturers and overseeing distribution. Examples include the UK's NHS and Brazil's Ministry of Health.

Regional centralized procurement is led by coalitions of states, provinces, or large health systems that band together for volume-based contracting. This model is prevalent in federated health systems, such as those in Canada and Australia, where provinces coordinate procurement under shared agreements to avoid duplication while respecting local autonomy [7].

Institutional-level centralized procurement refers to individual integrated delivery networks (IDNs), academic health systems, or large group purchasing organizations (GPOs) consolidating their purchasing functions across hospital networks. This model is increasingly common in the U.S., where large nonprofit systems like Kaiser Permanente and Vizient drive efficiencies through central sourcing units [8].

Each form varies in scope, operational complexity, and strategic objectives. While national models benefit from scale and policy coherence, regional and institutional models often offer more agile decision-making and customized supplier relationships. Regardless of level, centralization enhances inventory visibility, risk pooling, and cost predictability, particularly for high-volume, high-risk pharmaceutical categories.

2.2 Theoretical Foundations: Economies of Scale, Bargaining Power, Monopsony Effects

Centralized procurement models are underpinned by several economic theories, notably economies of scale, monopsony power, and transaction cost economics. These frameworks explain how centralization can produce cost efficiencies, supplier compliance, and market stabilization in pharmaceutical supply chains [9].

Economies of scale refer to cost advantages that arise from increased purchasing volume. Centralized systems consolidate demand across multiple institutions, enabling bulk ordering that reduces per-unit costs through quantity discounts, reduced logistics complexity, and streamlined contracting. This is especially beneficial in the generic and biologics markets, where large-volume guarantees can incentivize manufacturers to stabilize production [10].

Monopsony power occurs when a single buyer—or a highly consolidated group of buyers—controls a significant share of the market, giving it leverage to negotiate favorable terms, influence production priorities, or demand higher quality standards. While the concept often draws criticism in labor economics, in pharmaceutical procurement, monopsony power can mitigate price gouging and ensure equitable access by enabling price ceilings or pooled risk mechanisms [11].

Centralized procurement also reduces transaction costs, including administrative overhead from managing multiple contracts, duplicative regulatory audits, and inefficient invoicing. A central agency can coordinate quality assurance, enforce compliance standards, and negotiate unified delivery schedules, reducing friction between supplier and buyer networks.

Importantly, centralization supports supply risk mitigation by creating shared stockpiles, diversifying suppliers through multi-sourcing agreements, and coordinating early warning systems for disruptions. In contrast, decentralized models often compete for limited supply during crises, exacerbating hoarding and price spikes [12].

These theoretical advantages are amplified when paired with predictive analytics and digital procurement platforms—technologies explored further in the next section.

2.3 Global Case Comparisons and U.S. Applications

Global health systems offer a range of centralized procurement models that demonstrate both the feasibility and scalability of consolidated pharmaceutical sourcing. While contextual differences exist, each model offers insights applicable to the evolving U.S. landscape.

In the United Kingdom, the NHS Purchasing and Supply Agency (NHS PASA) historically negotiated national-level drug contracts, later succeeded by NHS Supply Chain, which now oversees over 600,000 product lines. This entity ensures transparent tendering, standard pricing, and direct supplier accountability, enabling rapid procurement during public health emergencies [13].

Brazil’s Unified Health System (SUS) exemplifies centralized procurement in middle-income economies. The Ministry of Health centrally procures vaccines, ARVs, and high-cost specialty medications, distributing them across state health secretariats. This model balances cost control with equity by mandating universal access, especially for neglected and rare disease treatments [14].

Denmark’s Amgros I/S, a national procurement body, coordinates drug purchasing for all hospital pharmacies. Amgros operates competitive tendering cycles and forecasts consumption trends, enabling real-time adjustment of supply contracts. The agency reportedly achieved 30–40% cost savings on hospital drugs after consolidation [15].

In the United States, centralized procurement has emerged in niche but growing applications. Civica Rx, a nonprofit pharmaceutical consortium launched in 2018, pools purchasing power from major health systems to manufacture or secure essential generic drugs facing chronic shortages. By offering fixed, transparent pricing and long-term contracts to suppliers, Civica helps reduce volatility and ensures consistent access [16].

Another example is the U.S. Department of Veterans Affairs (VA), which operates a centralized national formulary and negotiates drug pricing through the Federal Supply Schedule. This approach enables substantial cost savings while preserving access to high-value medications through tiered coverage and utilization review mechanisms [17].

Table 1: *Comparative Models of Centralized Pharmaceutical Procurement in Major Global Health Systems*

Country	**Model Type**	**Managing Entity**	**Key Outcomes**

Country	Model Type	Managing Entity	Key Outcomes
UK	National	NHS Supply Chain	Transparent pricing, rapid emergency response
Brazil	National	Ministry of Health	Equitable access, ARV and vaccine availability
Denmark	National	Amgros I/S	Hospital drug savings of 30–40%
USA	Institutional	Civica Rx / VA	Shortage reduction, fixed pricing, supply resilience

These case studies highlight that centralization, when designed with transparency, policy alignment, and technology integration, can dramatically improve supply chain security, fiscal control, and public health preparedness.

3. ROLE OF PREDICTIVE ANALYTICS AND AI IN SUPPLY CHAIN OPTIMIZATION

3.1 Forecasting Drug Demand and Preventing Shortages

One of the most urgent drivers of centralized procurement modernization is the ability to predict drug demand accurately and prevent shortages. AI-enabled forecasting models offer superior accuracy over traditional statistical methods by incorporating real-time data inputs such as electronic prescribing trends, patient acuity, seasonal illness patterns, and even socioeconomic variables [11].

Traditional forecasting tools in hospital pharmacy settings often rely on past usage trends or procurement cycles. These models may fail to anticipate sudden demand surges due to infectious disease outbreaks, new treatment guidelines, or geopolitical events disrupting global manufacturing. In contrast, machine learning (ML) models continuously learn from incoming data streams and adjust demand predictions with higher temporal sensitivity [12].

For example, a multi-center study by a regional GPO integrated ML-based forecasting with inventory management systems across six hospitals. Within eight months, backorder incidents dropped by 43%, and stockout rates for high-risk injectable medications fell to below 2% [13]. The AI system analyzed prescription fill patterns, inpatient bed occupancy rates, and weather data to anticipate usage spikes, especially during flu and allergy seasons.

Advanced forecasting systems also flag slow-moving stock and forecast expiry risks—enabling centralized depots to reallocate or rotate stock among facilities to minimize waste. AI algorithms have been deployed to monitor not only volume but also variation in demand by therapeutic class, predicting when alternative treatments may be needed due to substitution or discontinuation [14].



Figure 1: *Workflow diagram of AI-enabled centralized pharmaceutical supply chain infrastructure showing integration between prescribing systems, vendor portals, and predictive engines.*

By combining real-time data, historical patterns, and external disruption indicators, AI-based forecasting tools form the foundation of proactive procurement planning. These systems allow central procurement entities to negotiate more accurate volume commitments, avoid emergency purchases, and reduce hoarding behaviors during crises.

3.2 AI for Price Modeling, Supply Chain Risks, and Vendor Reliability

Another critical application of AI in centralized pharmaceutical procurement is price modeling and supplier risk analytics. Historically, drug price fluctuations have been difficult to predict due to opacity in manufacturer contracts, dynamic rebate structures, and limited insight into vendor behavior. AI models offer data-driven solutions by analyzing market signals, historical pricing patterns, and supply chain reliability metrics to inform value-based procurement [15].

AI-based price modeling systems evaluate cost components such as API origin, production capacity, transportation constraints, and macroeconomic variables like fuel costs or tariffs. These models allow procurement teams to simulate pricing scenarios across vendors and geographies. For instance, in a U.S.-based study of 72 formulary drugs, AI-enabled price forecasting reduced overspending by 11% compared to standard cost projection tools [16].

Supply chain risk assessment is another growing AI domain. ML algorithms now score vendors based on criteria such as delivery timeliness, regulatory compliance history, geographic concentration, labor strikes, or raw material dependency. Such models can incorporate structured data (e.g., FDA warning letters) and unstructured inputs (e.g., news feeds, social media reports, logistics alerts) to dynamically generate vendor reliability indices [17].

AI also helps identify single-source vulnerabilities within therapeutic classes. When a procurement office receives a quote for a critical antibiotic, the system can alert whether 80% of U.S. supply originates from one geographic region or whether that vendor has previously failed quality audits. These insights promote multi-sourcing and redundancy, core principles of supply chain resilience [18].

Furthermore, AI can enhance contract performance monitoring by tracking vendor adherence to lead times, fill rates, and pricing terms in real time. Automated flags can trigger renegotiation clauses or alternative sourcing when deviations exceed defined thresholds. Centralized platforms embedded with such models allow procurement officers to respond rapidly to early warning signs rather than reacting post-failure.

By merging AI-driven financial forecasting with operational risk signals, centralized procurement bodies can make more informed, defensible, and agile purchasing decisions that extend beyond lowest-cost selection to long-term supply assurance.

3.3 Integrating Predictive Analytics with Electronic Health Records and Pharmacy Informatics

The value of predictive analytics in procurement is further magnified when integrated with electronic health records (EHRs), computerized physician order entry (CPOE), and pharmacy informatics systems. These integrations create a real-time feedback loop that connects patient-level clinical data with enterprise-wide sourcing decisions, aligning procurement priorities with evolving care patterns [19].

For example, if EHR-integrated analytics detect a rising trend in heart failure admissions or chemotherapy protocol changes, this can trigger upstream procurement adjustments in diuretics, biologics, or infusion supplies. When embedded in clinical decision support systems (CDSS), AI tools can even forecast which formularies are likely to see increased utilization due to seasonal guidelines, medication recalls, or payer policy updates [20].

In one case, a major academic health system integrated AI-driven procurement dashboards with Epic and Cerner EHRs across 12 hospitals. Over 14 months, this led to a 17% improvement in procurement-cycle responsiveness and reduced formulary deviation incidents by 22% [21]. Pharmacists received early warnings of high-variance prescribing trends, which helped refine order frequency and improve inventory turns.

Furthermore, pharmacy informatics platforms can leverage predictive models to automate therapeutic interchange suggestions during shortages, offering real-time clinical alternatives that align with formulary restrictions and procurement availability. AI modules also support drug utilization reviews (DUR), alerting clinicians when prescribing patterns deviate significantly from population baselines or reimbursement criteria [22].

Through these integrated systems, predictive procurement becomes a living process—adaptive to patient acuity, local practice variation, and emerging clinical data. This convergence of analytics, EHRs, and pharmacy operations ensures that supply chain decisions are not only cost-efficient but also clinically aligned and timely.

4. CLINICAL IMPLICATIONS: CARDIOVASCULAR MEDICATION ACCESS AND HEALTH OUTCOMES

4.1 Importance of Continuous Access to Antihypertensives, Statins, and Anticoagulants

Cardiovascular disease (CVD) remains the leading cause of mortality in the United States, with hypertension, hyperlipidemia, and atrial fibrillation among its most prevalent contributors. Clinical management of these conditions hinges on consistent, long-term access to pharmacologic therapies, particularly antihypertensives, statins, and anticoagulants [15]. Interruptions in drug supply for these classes can lead to adverse events such as stroke, myocardial infarction, and sudden cardiac death.

Therapeutic continuity is especially critical in the elderly and those with comorbidities who depend on multiple medications to maintain baseline cardiovascular health. Yet, medication access is often compromised by stockouts, unaffordable out-of-pocket costs, or inconsistent formularies across providers. Decentralized procurement systems exacerbate these issues by fragmenting supply lines, hindering coordinated inventory oversight, and increasing susceptibility to local disruptions [16].

Antihypertensives like amlodipine or lisinopril must be taken daily and long-term, with even brief lapses associated with increased systolic blood pressure and stroke risk. Statins, used to manage atherosclerotic risk, lose efficacy with inconsistent adherence. Anticoagulants like warfarin or DOACs (e.g., apixaban) are particularly sensitive—gaps in access can precipitate thromboembolic events with life-threatening consequences [17].

Centralized procurement reduces these risks by smoothing supply chain variability, standardizing purchasing across regions, and enabling proactive forecasting of demand surges based on clinical utilization. When embedded with AI-driven analytics, centralized systems can flag risks for therapeutic class shortages and trigger mitigation strategies before stockouts occur. This is particularly beneficial in cardiology, where treatment outcomes are highly time-sensitive and medication continuity is non-negotiable [18].

4.2 Impact of Centralized Procurement on Medication Adherence and Therapy Persistence

Medication adherence—the extent to which patients take medications as prescribed—remains a persistent barrier to effective cardiovascular disease management. It is estimated that nearly 50% of patients prescribed antihypertensives or statins are nonadherent after one year, with consequences ranging from hospital readmission to avoidable mortality [19]. While many factors influence adherence, supply consistency and affordability are among the most modifiable system-level drivers.

Centralized procurement models can significantly influence both. By consolidating purchasing and enabling long-term contracts with fixed pricing, central entities reduce retail and institutional cost volatility. This facilitates formulary stability and price predictability—allowing patients and providers to develop long-term medication management plans without fear of mid-treatment disruptions due to shortages or cost spikes [20].

Moreover, centralized systems can leverage bulk purchasing to supply public assistance programs (e.g., 340B hospitals, Medicaid networks) with high-demand cardiovascular medications at significantly reduced cost. These savings can be reinvested in adherence interventions, such as medication synchronization, multi-month dispensing, or community pharmacy delivery, which have all been shown to improve persistence in chronic CVD care [21].

For example, a study conducted across four health systems participating in a centralized procurement pilot found that fixed quarterly ordering for antihypertensives led to a 23% increase in patient refill consistency. The same cohort reported a 17% decrease in therapeutic switching due to stock-based substitutions, reinforcing the role of procurement consistency in supporting clinical continuity [22].

Another often-overlooked benefit of centralized procurement is the ability to track drug availability against adherence KPIs using integrated dashboards. When combined with pharmacy benefit management and EHR data, these tools can flag potential gaps in therapy at the population level and initiate case manager follow-up. In settings where stockouts had previously disrupted therapy, the introduction of predictive analytics into centralized procurement led to a 31% decrease in days without medication across antihypertensive and statin users [23].

These improvements extend beyond clinical metrics. Improved therapy persistence has been linked to reductions in downstream costs—including fewer hospital admissions for hypertensive emergencies, decreased use of high-cost anticoagulation bridging, and reduced cardiovascular readmissions. Thus, centralized procurement not only improves health outcomes but also alleviates financial pressures on health systems managing chronic disease populations.

4.3 Evidence from Health Systems Using Centralized Analytics-Enabled Supply Chains

Several health systems in the United States have begun deploying centralized procurement strategies supported by predictive analytics and EHR integration, with promising results in cardiovascular outcomes. These implementations demonstrate the value of combining infrastructure modernization with data-driven supply management, particularly in high-risk therapeutic areas [24].

One notable example is the University of Pittsburgh Medical Center (UPMC), which implemented a centralized supply chain for high-volume cardiovascular medications across its hospital network. Using real-time analytics linked to prescribing trends and inpatient volumes, UPMC's centralized procurement division reduced formulary discontinuity and achieved a 19% decrease in pharmacy-related care delays over a 12-month period [25]. Patients with congestive heart failure were less likely to experience discharge prescription delays, improving care transitions and reducing 30-day readmissions.

Similarly, a regional purchasing consortium in California leveraged Civica Rx's fixed-price contracting model to stock essential cardiovascular drugs—including beta-blockers and antiarrhythmics—across public health facilities. Within 18 months, the consortium reported a 26% decrease in stockout incidents and a 9% improvement in statin adherence rates among Medicare beneficiaries, as tracked via pharmacy claims and refill logs [26].

Predictive models have also been applied to anticoagulant therapy management. In a pilot involving a Midwestern integrated health system, a centralized dashboard tracked apixaban and warfarin utilization trends across 18 clinics. The dashboard alerted pharmacy leads when inpatient anticoagulation usage spiked due to seasonal thrombotic risk factors (e.g., flu season, reduced mobility). As a result, procurement schedules were adjusted in advance, avoiding emergency orders and maintaining uninterrupted patient access during peak periods [27].

Table 2: *Summary of Cardiovascular Outcome Improvements Linked to Improved Pharmaceutical Access*

Metric	Pre-Centralization	Post-Centralization	Relative Improvement
Statin Refill Adherence (PDC ≥ 80%)	62%	75%	+21%
Antihypertensive Therapy Persistence (12-month)	58%	71%	+22%
30-Day Readmission (Heart Failure)	17.8%	13.4%	–25%
Formulary Disruption Incidence	23 cases/month	9 cases/month	–61%

These cases confirm that analytics-enabled centralized procurement is not just a financial strategy—it is a clinical intervention tool. By aligning drug availability with disease management strategies, health systems can enhance quality, optimize outcomes, and foster systemic reliability across the continuum of cardiovascular care [28].

5. BROADER ECONOMIC AND OPERATIONAL BENEFITS OF CENTRALIZED, AI-DRIVEN SYSTEMS

5.1 Cost Savings Through Bulk Contracting, Reduced Markups, and Avoided Waste

One of the most quantifiable benefits of centralized pharmaceutical procurement is cost containment, primarily driven by bulk contracting, decreased pricing markups, and waste mitigation. Centralized systems consolidate purchasing volumes across multiple facilities, enabling health systems to negotiate lower unit costs and long-term fixed pricing that protects against volatility [19].

Bulk procurement enables economies of scale that decentralized institutions cannot individually achieve. By aggregating demand across a state network or an integrated delivery system (IDS), organizations can secure preferential rates from manufacturers and distributors. For example, Civica Rx has reported achieving cost reductions of 30–50% on select injectable generics by bypassing intermediaries and contracting directly with suppliers for guaranteed volumes [20].

Centralized contracts also minimize the impact of multi-tier distribution markups. In conventional models, the same drug may pass through wholesalers, GPOs, repackagers, and logistics agents—each adding a cost layer. In contrast, centralized contracts often allow for direct sourcing or single-agent distribution, eliminating redundant overhead and reducing total acquisition cost [21].

Another key advantage is reduced drug wastage. Fragmented procurement often leads to overstocking at one site while another experiences a shortage. Centralized systems with shared inventory visibility allow excess stock to be redirected before expiration. Predictive algorithms further optimize reorder thresholds, minimizing the need for emergency purchases that often come at premium prices [22].

Overall, centralized procurement achieves substantial cost savings not by merely paying less per unit, but by redesigning the supply chain to minimize inefficiencies, markups, and demand-supply mismatches.

5.2 Operational Efficiency in Inventory Management, Warehousing, and Cold-Chain Logistics

Beyond price savings, centralized procurement models offer significant gains in operational efficiency, especially across core logistics functions such as inventory control, warehousing, and cold-chain integrity. These efficiencies result from harmonized protocols, shared digital infrastructure, and predictive inventory management [23].

In decentralized environments, hospitals manage inventories independently, resulting in redundant processes, duplicated safety stocks, and inconsistent tracking methods. Centralized models resolve these inefficiencies by standardizing inventory policies, consolidating warehousing operations, and leveraging regional distribution centers to improve replenishment speed and reduce overhead [24].

Central warehouses managed by centralized procurement entities can serve multiple facilities simultaneously, implementing automated picking systems, RFID tracking, and temperature-sensitive monitoring for biologics and vaccines. A large health system in the Midwest that transitioned to a centralized warehouse model reported a 28% reduction in warehouse labor hours and a 14% decrease in inventory holding costs within the first year [25].

Cold-chain logistics—critical for the distribution of temperature-sensitive drugs like insulin, chemotherapy, and certain vaccines—benefits immensely from centralized oversight. Instead of fragmented cold storage at individual hospitals, central hubs can ensure consistent environmental controls and maintain regulatory compliance throughout last-mile delivery. Integration with GPS-enabled monitoring tools provides real-time alerts on temperature excursions, ensuring product integrity [26].

Moreover, predictive analytics embedded in inventory systems optimize stocking decisions by analyzing real-time consumption, seasonal demand shifts, and prescribing trends. This reduces expiries, improves stock turns, and ensures product availability during surges, such as pandemics or drug recalls.



Figure 2: *Before-and-after operational metrics from centralized supply chain adoption, showing improvements in stock accuracy, delivery lead time, and labor utilization.*

These operational advancements ensure that procurement reforms extend beyond contracting—transforming the entire pharmaceutical fulfillment process into a lean, data-driven engine.

5.3 Labor Savings and Workflow Simplification Across Hospital Systems

Centralized procurement doesn't just impact cost and logistics—it also produces meaningful labor savings and workflow simplification, especially in hospital pharmacy and supply chain operations. As procurement functions are centralized and automated, staff roles are redefined around analytics, exception handling, and clinical collaboration rather than manual ordering and reconciliation [27].

In traditional settings, pharmacy teams dedicate significant time to sourcing drugs, confirming deliveries, handling backorders, and managing stock levels. Each site operates independently, leading to duplicated efforts and communication gaps. Centralized models replace these localized tasks with shared service centers that manage procurement on behalf of all facilities within the network, reducing transaction volume and manual work [28].

Staff in individual hospitals are freed to focus on clinical support roles—such as medication therapy management, antimicrobial stewardship, or regulatory reporting. At a five-hospital system in the Southeast, transitioning to centralized procurement resulted in a 21% reduction in procurement labor hours and a reallocation of pharmacy technicians to inpatient rounding and reconciliation programs [29].

Workflow automation tools also reduce human error. AI-powered platforms automatically match invoices to shipments, flag price discrepancies, and generate suggested purchase orders based on forecasted need. These systems reduce dependency on spreadsheets and email chains, accelerating procurement cycles and eliminating redundancy.

Training and oversight are also streamlined. Instead of onboarding buyers at every location, centralized systems develop standardized protocols and provide targeted training for procurement specialists. This centralization creates accountability, transparency, and role clarity across the entire supply function [30].

Ultimately, labor optimization complements financial and logistical improvements—building a more agile, scalable, and clinically integrated procurement workforce.

6. CHALLENGES AND RISKS OF CENTRALIZED, AI-INTEGRATED SUPPLY CHAINS

6.1 Data Interoperability, Infrastructure Gaps, and Resistance to AI Adoption

The successful implementation of centralized, AI-enabled pharmaceutical procurement depends heavily on data interoperability and the strength of digital infrastructure across participating institutions. Unfortunately, the fragmented nature of U.S. healthcare IT systems often presents a major barrier. Many hospitals use legacy enterprise resource planning (ERP) or pharmacy management software that is incompatible with AI-based forecasting tools or centralized inventory platforms [23].

Without standardized data formats and integration frameworks (such as HL7 FHIR), real-time information sharing becomes cumbersome. Disparate databases can lead to data silos, duplication, and incomplete analytics, undermining the predictive capabilities of AI systems. Even within large IDNs, inconsistencies between EHR systems and inventory platforms hinder seamless visibility into drug usage trends [24].

Infrastructure limitations are also common in rural or safety-net hospitals, where bandwidth, cybersecurity readiness, and technical workforce constraints delay adoption. These gaps can lead to unequal benefits of centralization, where digitally advanced facilities realize efficiency gains while others lag behind [25].

Furthermore, there is organizational resistance to AI adoption, often rooted in mistrust, unfamiliarity, or fear of workforce displacement. Procurement teams may question the reliability of AI-generated forecasts or see automation as a threat to job roles. In one survey of 65 hospital pharmacy directors, 42% cited lack of trust in AI systems as a top barrier to adoption [26].

Overcoming these challenges requires phased implementation, robust interoperability frameworks, and extensive training programs. Pilot initiatives that demonstrate tangible operational improvements, coupled with transparent governance models, can build confidence and foster a culture of data-driven procurement transformation.

6.2 Risks of Supplier Dependence, Procurement Rigidity, and Monopolistic Practices

Centralized procurement, while promoting efficiency and cost control, also introduces systemic risks related to supplier dependence and reduced flexibility. Over-reliance on a limited number of vendors—especially in the context of national contracts—can create vulnerability if a single supplier experiences production delays, quality failures, or geopolitical disruptions [27].

In centralized systems, procurement rigidity may emerge when contract terms restrict local substitutions or mandate adherence to pre-approved formularies regardless of real-time availability. While this standardization simplifies operations, it can reduce responsiveness during clinical exceptions or emergencies. For instance, if a supplier fails to deliver an anticoagulant on time, but contract exclusivity prohibits sourcing from local alternatives, patient care may suffer [28].

Moreover, centralized contracts can unintentionally promote monopolistic practices. Dominant GPOs or procurement hubs may marginalize smaller vendors or innovators that cannot meet high-volume thresholds or pricing constraints. This concentration of market power may lead to reduced competition, innovation stagnation, and longer-term price normalization above competitive levels [29].

These risks can be mitigated through multi-sourcing strategies, contract flexibility clauses, and periodic vendor audits. Central procurement agencies should maintain secondary suppliers, stagger tender timelines, and include early exit provisions in case of performance failure. Some systems have adopted tiered contracting models that allow for both primary and contingency vendors to ensure supply continuity without diluting economies of scale [30].

A balance must be struck between the efficiency benefits of centralization and the operational resilience afforded by diversity and adaptability in procurement relationships.

6.3 Ethical Concerns: Data Governance, Equity, and Clinical Autonomy

As AI becomes more embedded in pharmaceutical procurement, ethical concerns surrounding data governance, equity, and clinical autonomy must be critically addressed. AI systems rely on vast datasets, often drawn from patient records, prescribing behavior, and utilization metrics. Without strong governance, this data can be exposed to misuse, breaches, or biased algorithmic outputs that disproportionately affect marginalized populations [31].

Transparency is a foundational principle. Procurement algorithms that prioritize lowest-cost purchasing may unintentionally deprioritize access to specialty or orphan drugs needed by smaller or less vocal patient populations. Similarly, models that optimize for aggregate usage patterns can ignore rare but high-risk conditions, reinforcing inequities already prevalent in access to essential medications [32].

Consent and data sovereignty also come into play. While de-identified data is often used, patients and clinicians have limited visibility into how procurement decisions are influenced by their health records. Some stakeholders argue that algorithmic inputs should be governed by institutional review boards (IRBs) or patient advocacy panels to ensure ethical use of clinical information [33].

Clinical autonomy may also be compromised if procurement systems enforce rigid formularies based on algorithmic recommendations. While standardization supports cost control, prescribers must retain the authority to deviate based on patient-specific clinical judgments. Procurement platforms must allow for flagging of exceptions, documentation of rationale, and appeal mechanisms.

Table 3: *Summary of Risks and Mitigation Strategies in Centralized AI-Enabled Procurement Systems*

Risk Category	Example	Mitigation Strategy
Interoperability	Disparate EHR systems block real-time analytics	HL7 FHIR integration, vendor-neutral architecture

Risk Category	Example	Mitigation Strategy
Supplier Dependence	Contract with single manufacturer	Multi-vendor tiers, audit protocols
Equity Bias	AI underrepresents rare disease populations	Model validation against equity benchmarks
Clinical Inflexibility	Formulary rigidly enforced by algorithms	Override options, clinician escalation workflow
Data Privacy	Improper use of clinical or pharmacy data	Role-based access, ethics governance boards

Designing centralized procurement systems that preserve patient-centered care, clinician agency, and ethical stewardship of data is essential for sustainable and equitable digital transformation.

7. POLICY RECOMMENDATIONS AND STRATEGIC FRAMEWORK FOR IMPLEMENTATION

7.1 Designing Scalable, Federated Procurement Models with AI Augmentation

To overcome the barriers of fragmentation while preserving operational agility, the U.S. healthcare system must embrace federated centralized procurement models—systems that align around shared objectives while allowing institutional customization. These models are especially effective when augmented by AI, which enables real-time coordination, predictive decision-making, and cross-platform synchronization [27].

In a federated model, procurement is centralized at the regional or health system level but designed with modular interfaces that allow individual providers to customize formularies, delivery schedules, or contract clauses based on clinical or geographic needs. AI serves as the central nervous system of this structure, continuously aggregating consumption data, forecasting demand surges, optimizing vendor portfolios, and flagging contractual noncompliance across nodes [28].

For example, multiple academic medical centers within a state could pool purchasing through a shared digital procurement hub while using AI to accommodate nuanced clinical workflows and treatment protocols. Each node contributes anonymized, real-time prescribing and inventory data, which the AI analyzes to generate volume targets and recommend dynamic pricing adjustments based on usage trends, emerging shortages, or seasonal epidemiological forecasts [29].

Scalability is achieved through cloud-native data infrastructure and secure APIs that interface with EHRs, ERP systems, wholesaler platforms, and national surveillance databases. Machine learning models can be trained on federated datasets, allowing the system to detect regional variability in usage or risk exposure without compromising institutional autonomy. This architecture supports simultaneous visibility and local optimization—enabling context-aware decision support tailored to patient mix, population health profiles, and payer mandates.

Importantly, federated models provide a buffer against over-centralization risks, such as inflexible sourcing mandates, single-vendor dependency, or diminished frontline discretion. When governed transparently and underpinned by adaptive AI algorithms, these systems combine the strategic strength of scale with the operational flexibility essential to meeting diverse clinical and logistical realities. The future of pharmaceutical procurement in the U.S. may well rest in this hybrid approach, balancing collective resilience with decentralized innovation.



Figure 3: *Strategic framework for AI-integrated centralized pharmaceutical procurement in U.S. systems, showing feedback loops between hospitals, payers, manufacturers, and predictive engines.*

7.2 Governance and Transparency in Pricing, Access, and Decision-Making

As centralized procurement systems expand, governance and transparency must be prioritized to maintain equity, trust, and legal compliance. Without proper oversight, consolidation risks evolving into opaque monopolies that favor select vendors or institutions [30].

Key governance principles include clear delineation of responsibilities across contracting, quality assurance, and AI algorithm management. Independent oversight boards composed of pharmacists, physicians, data scientists, and ethicists should review procurement algorithms for accuracy, bias, and relevance to clinical care pathways. Version control, audit logs, and explainability thresholds must be built into algorithmic systems [31].

Transparency in pricing is particularly critical. All participating entities should have access to contract terms, rebate structures, and comparative pricing dashboards. AI can support this by automating benchmarking reports across geographies, enabling equitable cost comparisons without exposing sensitive negotiation data [32].

Access must be universal and predictable. Procurement prioritization—especially during shortages—should follow published ethical frameworks and be auditable to prevent favoritism. Allocation algorithms must incorporate clinical urgency, epidemiological trends, and population health equity indicators rather than volume or institutional clout alone [33].

By embedding accountability and transparency at every tier of procurement governance, AI-powered systems can enhance—not undermine—trust and fairness in drug access and supply management.

7.3 Engaging Stakeholders: Payers, Providers, Policymakers, and Patients

A successful transition to AI-augmented centralized procurement depends on multi-stakeholder engagement. Each actor—payers, providers, policymakers, and patients—plays a distinct role in shaping, adopting, and sustaining these systems.

Payers, including public and private insurers, are instrumental in aligning procurement incentives with reimbursement structures. Their collaboration ensures that formulary design and price negotiations reflect value-based care principles and prevent misaligned cost shifting. Predictive analytics can help insurers forecast claim patterns and adjust coverage terms in line with procurement dynamics [34].

Providers must be active co-designers. Physicians and pharmacists need training to interpret AI recommendations and confidence that procurement rules won't compromise clinical autonomy. Institutional leaders must ensure that frontline teams are involved in pilot testing, feedback loops, and performance audits. Local champions help translate data-driven tools into cultural adoption [35].

Policymakers must modernize regulatory frameworks to support secure data sharing, outcome-based contracting, and cross-system collaboration. Federal agencies can provide funding for infrastructure upgrades, algorithm validation research, and incentives for early adopters—much like prior initiatives for EHR adoption under the HITECH Act [36].

Patients, as the ultimate beneficiaries, must be included in governance structures, especially regarding drug prioritization and ethical use of data. Transparent communication, appeals processes, and consent mechanisms are essential for public legitimacy.

Only through inclusive governance and proactive engagement can AI-integrated procurement evolve from a technical reform into a patient-centered, value-generating healthcare transformation.

8. CONCLUSION

8.1 Recap of Economic and Clinical Value

The exploration of centralized procurement models throughout this article has underscored their significant economic and clinical value to U.S. healthcare systems. By consolidating pharmaceutical purchasing power, institutions can reduce per-unit drug costs, limit the influence of intermediaries, and stabilize pricing across therapeutic classes. These financial benefits are amplified by operational efficiencies achieved in warehousing, inventory management, and cold-chain logistics—areas that typically incur substantial overhead in decentralized systems.

From a clinical perspective, centralized procurement ensures timely, uninterrupted access to essential medications, which directly supports chronic disease management, emergency care preparedness, and equitable patient outcomes. Enhanced forecasting tools, predictive analytics, and real-time integration with clinical workflows enable better alignment between drug availability and treatment protocols. As demonstrated in cardiovascular disease management, uninterrupted access to key therapies such as antihypertensives and statins improves adherence and reduces adverse events.

The labor savings and process simplification achieved through centralized models also allow healthcare professionals to focus more on clinical responsibilities rather than administrative tasks, improving care quality and job satisfaction. When procurement is intelligently automated, hospital systems gain not only fiscal discipline but also operational clarity.

Taken together, centralized procurement represents a high-leverage intervention that addresses cost, access, and quality in one unified strategy. It offers a rare convergence of financial prudence and clinical benefit—a necessary combination in today’s resource-constrained, outcome-driven healthcare environment.

8.2 Strategic Outlook for U.S. Healthcare Systems

As U.S. healthcare systems evolve in response to shifting market dynamics, regulatory pressures, and patient expectations, centralized procurement will likely play an increasingly strategic role. The trend toward consolidation among providers, growth of integrated delivery networks, and expansion of public-private partnerships all set the stage for wider adoption of collaborative sourcing mechanisms.

Federated procurement models—those that allow regional or institutional autonomy within a unified negotiation and contracting framework—are particularly well-suited to the diverse U.S. healthcare landscape. These models can scale across states or health systems while preserving flexibility and responsiveness to local needs. With AI augmentation, such systems become even more powerful, offering real-time visibility, predictive insight, and supply risk mitigation.

Health systems that proactively invest in centralized infrastructure and analytics will be positioned to navigate disruptions more effectively, whether caused by global pandemics, economic shocks, or supply chain failures. Moreover, centralized systems can serve as platforms for broader innovations in drug utilization review, population health management, and personalized medicine supply chains.

At the policy level, there is increasing momentum toward greater price transparency, standardized data exchange protocols, and regulatory support for group purchasing entities and public-sector procurement initiatives. These trends suggest a favorable environment for policy alignment and investment in centralized models.

Ultimately, the strategic outlook is clear: centralized pharmaceutical procurement—especially when enabled by intelligent technologies—will become a cornerstone of future-ready healthcare organizations committed to delivering high-value care.

8.3 Final Reflections on Balancing Efficiency, Innovation, and Equitable Access

While centralized procurement offers clear efficiencies and system-wide advantages, its long-term success will depend on striking the right balance between efficiency, innovation, and equity. Streamlining operations and reducing costs must not come at the expense of innovation in drug development, diversity of supply, or local clinical decision-making.

Equitable access to medicines remains the ultimate measure of any procurement strategy. As central entities gain leverage, they must also embrace responsibility—ensuring that procurement decisions do not disproportionately disadvantage rural facilities, underserved populations, or smaller providers. Attention must also be paid to therapeutic equity, making sure that medications for rare diseases or low-income patients are not marginalized in pursuit of volume-driven savings.

Innovation must also be preserved. While centralized contracts may prioritize cost-effectiveness and formulary standardization, they must allow space for emerging therapies, personalized treatments, and off-label use where clinically justified. Procurement protocols should integrate feedback from clinicians and ensure that formularies reflect both evidence-based practice and patient-specific needs.

In the end, centralized pharmaceutical procurement is not just a logistical exercise—it is a strategic lever for health system transformation. When designed thoughtfully and governed transparently, it can harmonize financial stewardship with public health imperatives. It can deliver efficiency without sacrificing innovation and achieve scale without abandoning sensitivity to local realities.

As healthcare continues its complex evolution, centralized procurement—guided by data, ethics, and collaboration—offers a compelling path forward. It stands as both a solution to today's challenges and a foundation for tomorrow's sustainable, equitable, and intelligent healthcare ecosystem.

REFERENCE

1. Monlezun DJ. The thinking healthcare system: Artificial intelligence and human equity. Elsevier; 2023 Feb 17.
2. Elijah Olagunju. Cost-Benefit Analysis of Pharmacogenomics Integration in Personalized Medicine and Healthcare Delivery Systems. *International Journal of Computer Applications Technology and Research.* 2023;12(12):85–100. Available from: https://doi.org/10.7753/IJCATR1212.1013
3. Olayinka OH. Data driven customer segmentation and personalization strategies in modern business intelligence frameworks. *World Journal of Advanced Research and Reviews*. 2021;12(3):711-726. doi: https://doi.org/10.30574/wjarr.2021.12.3.0658
4. Firouzi F, Farahani B, Barzegari M, Daneshmand M. AI-driven data monetization: The other face of data in IoT-based smart and connected health. IEEE Internet of Things Journal. 2020 Sep 30;9(8):5581-99.
5. Pelumi Oladokun; Adekoya Yetunde; Temidayo Osinaike; Ikenna Obika. "Leveraging AI Algorithms to Combat Financial Fraud in the United States Healthcare Sector." Volume. 9 Issue.9, September - 2024 International Journal of Innovative Science and Research Technology (IJISRT), www.ijisrt.com. ISSN - 2456-2165, PP:- 1788-1792, https://doi.org/10.38124/ijisrt/IJISRT24SEP1089
6. Okeke CMG. Evaluating company performance: the role of EBITDA as a key financial metric. *Int J Comput Appl Technol Res*. 2020;9(12):336–349
7. Oluwafemi Oloruntoba. Green cloud computing: AI for sustainable database management. *World Journal of Advanced Research and Reviews.* 2024;23(03):3242–3257. Available from: https://doi.org/10.30574/wjarr.2024.23.3.2611
8. Chukwunweike JN, Chikwado CE, Ibrahim A, Adewale AA Integrating deep learning, MATLAB, and advanced CAD for predictive root cause analysis in PLC systems: A multi-tool approach to enhancing industrial automation and reliability. World Journal of Advance Research and Review GSC Online Press; 2024. p. 1778–90. Available from: https://dx.doi.org/10.30574/wjarr.2024.23.2.2631
9. Petmesidou M, Pavolini E, Guillén AM. South European healthcare systems under harsh austerity: a progress–regression mix?. South European Society and Politics. 2014 Jul 3;19(3):331-52.
10. Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, Kozlakidis Z, van Belkum A. Consolidation of clinical microbiology laboratories and introduction of transformative technologies. Clinical microbiology reviews. 2020 Mar 18;33(2):10-128.
11. Agrawal A, Gans J, Goldfarb A. Power and prediction: The disruptive economics of artificial intelligence. Harvard Business Press; 2022 Nov 15.
12. Yang H, Zhang S, Liu R, Krall A, Wang Y, Ventura M, Deflitch C. Epidemic informatics and control: A holistic approach from system informatics to epidemic response and risk management in public health. InAI and Analytics for Public Health-Proceedings of the 2020 INFORMS International Conference on Service Science 2021 (pp. 1-46). Berlin/Heidelberg, Germany: Springer.
13. Ghosh P, Biswas A, Ghosh S. Fundamentals and technicalities of big data and analytics. InIntelligent systems in healthcare and disease identification using data science 2023 Oct 10 (pp. 51-106). Chapman and Hall/CRC.
14. Chukwunweike JN, Praise A, Osamuyi O, Akinsuyi S and Akinsuyi O, 2024. AI and Deep Cycle Prediction: Enhancing Cybersecurity while Safeguarding Data Privacy and Information Integrity. https://doi.org/10.55248/gengpi.5.0824.2403
15. Pappas H, Frisch P. Leveraging technology as a response to the COVID pandemic: Adapting diverse technologies, workflow, and processes to optimize integrated clinical management. CRC Press; 2022 Dec 30.
16. Olawale MA, Ayeh AA, Adekola FO, Precious AS, Joshua AO, Timothy O. A Review on the Intersection of Artificial Intelligence on Building Resilient Infrastructure, Promoting Inclusive and Sustainable Industrialization and Fostering Innovation. Int. J. Eng. Modern Technol. 2023;9(3):1-31.

17. Rye S, Göransson P. Organizing a Competence Center at a Public Hospital to Increase Artificial Intelligence Impact-Key Learnings from a Comparative Study Across Six Large Organizations.
18. Yang H, Zhang S, Liu R, Krall A, Wang Y, Ventura M, Deflitch C. Epidemic informatics and control: A review from system informatics to epidemic response and risk management in public health. InAI and Analytics for Public Health: Proceedings of the 2020 INFORMS International Conference on Service Science 2022 (pp. 1-58). Springer International Publishing.
19. Crawford JM, Aspinall MG. The business value and cost–effectiveness of genomic medicine. Personalized Medicine. 2012 May 1;9(3):265-86.
20. Steingrüber S, Gadanya M. Weak links: How corruption affects the quality and integrity of medical products and impacts on the Covid-19 response. U4 Issue. 2021 Dec 1.
21. Nyhan MM. The promise of digital health: addressing non-communicable diseases to accelerate universal health coverage in LMICs.
22. Brown D. Artificial Intelligence for Accelerating Nuclear Applications, Science, and Technology. Brookhaven National Laboratory (BNL), Upton, NY (United States); 2022 Jul 1.
23. Hays P, Hays P. Alliances: Knowledge Infrastructures, and the Digitization of Precision Health. Advancing Healthcare Through Personalized Medicine. 2021:99-139.
24. Hagerty A, Rubinov I. Global AI ethics: a review of the social impacts and ethical implications of artificial intelligence. arXiv preprint arXiv:1907.07892. 2019 Jul 18.
25. Zekos GI, Zekos GI. AI Risk Management. Economics and Law of Artificial Intelligence: Finance, Economic Impacts, Risk Management and Governance. 2021:233-88.
26. Jones L, Hameiri S. COVID-19 and the failure of the neoliberal regulatory state. Review of international political economy. 2022 Jul 4;29(4):1027-52.
27. Farahani B, Firouzi F, Luecking M. The convergence of IoT and distributed ledger technologies (DLT): Opportunities, challenges, and solutions. Journal of Network and Computer Applications. 2021 Mar 1;177:102936.
28. Jones H. When AI rules the world: China, the US, and the race to control a smart planet. Bombardier Books; 2022 Sep 20.
29. Sun S, Ching AH. Social systems matter: Precision medicine, public health, and the medical model. East Asian Science, Technology and Society: An International Journal. 2021 Oct 2;15(4):439-66.
30. Agarwal L. Building a Resilient Digital Health Ecosystem in India. Accelerating Global Health. 2023;82.
31. Shi ZR, Wang C, Fang F. Artificial intelligence for social good: A survey. arXiv preprint arXiv:2001.01818. 2020 Jan 7.
32. Abbasi S, Jung BK. White Paper-Overview and Insight: Performance of Digital Health Systems During the COVID-19 Pandemic. Overview and Insight: Performance of Digital Health Systems During the COVID-19 Pandemic. 2023 Jan 25:1-97.
33. Kissinger HA, Schmidt E, Huttenlocher D. The age of AI: and our human future. Hachette UK; 2021 Nov 2.
34. Aarden E. Constitutions of justice in genetic medicine: distributing diagnostics for familial hypercholesterolemia in three European countries. Critical Policy Studies. 2016 Apr 2;10(2):216-34.
35. Zuboff S. Surveillance capitalism or democracy? The death match of institutional orders and the politics of knowledge in our information civilization. Organization Theory. 2022 Nov;3(3):26317877221129290.
36. Hendrycks D, Mazeika M, Woodside T. An overview of catastrophic AI risks. arXiv preprint arXiv:2306.12001. 2023 Jun 21.